Key Points
- Insider buying: Fiorenzo Villani purchased 10,000 Portage Biotech shares at $4.40 each, investing $44,000 and increasing his position by 25.72% to 48,886 shares. He has made several additional purchases since September 9.
- Stock performance and financial position: ALP traded up 4.4% to $4.54, with a $7.04 million market capitalization and a 12-month range of $3.20 to $690.00. The company reported $0.05 million in quarterly revenue and analysts expect a full-year loss of $14 per share.
- Analyst outlook: Coverage is largely cautious, with two Hold ratings and one Sell rating, producing a consensus rating of Reduce and a $12.50 price target.
Portage Biotech Inc. (NASDAQ:ALP - Get Free Report) insider Fiorenzo Villani acquired 10,000 shares of the stock in a transaction dated Tuesday, September 22nd. The shares were bought at an average cost of $4.40 per share, for a total transaction of $44,000.00. Following the acquisition, the insider owned 48,886 shares in the company, valued at $215,098.40. The trade was a 25.72% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.
Fiorenzo Villani also recently made the following trade(s):
- On Wednesday, September 16th, Fiorenzo Villani bought 4,265 shares of Portage Biotech stock. The stock was bought at an average price of $4.05 per share, with a total value of $17,273.25.
- On Tuesday, September 15th, Fiorenzo Villani bought 7,900 shares of Portage Biotech stock. The shares were bought at an average cost of $4.15 per share, with a total value of $32,785.00.
- On Tuesday, September 15th, Fiorenzo Villani bought 10,382 shares of Portage Biotech stock. The shares were bought at an average cost of $4.07 per share, with a total value of $42,254.74.
- On Monday, September 14th, Fiorenzo Villani purchased 2,000 shares of Portage Biotech stock. The shares were bought at an average price of $4.16 per share, for a total transaction of $8,320.00.
- On Wednesday, September 9th, Fiorenzo Villani purchased 7,000 shares of Portage Biotech stock. The stock was purchased at an average cost of $5.07 per share, for a total transaction of $35,490.00.
Portage Biotech Trading Up 4.4%
NASDAQ:ALP opened at $4.54 on Thursday. The company's 50 day moving average is $8.82 and its 200-day moving average is $13.95. The company has a quick ratio of 0.31, a current ratio of 0.31 and a debt-to-equity ratio of 0.01. Portage Biotech Inc. has a 12 month low of $3.20 and a 12 month high of $690.00. The firm has a market cap of $7.04 million, a price-to-earnings ratio of -0.01 and a beta of 0.54.
Portage Biotech (NASDAQ:ALP - Get Free Report) last posted its quarterly earnings data on Thursday, July 16th. The company reported $23.75 earnings per share (EPS) for the quarter. The firm had revenue of $0.05 million for the quarter. Equities analysts anticipate that Portage Biotech Inc. will post -14 EPS for the current year.
Analysts Set New Price Targets
ALP has been the topic of several research analyst reports. HC Wainwright assumed coverage on Portage Biotech in a research report on Monday, August 17th. They issued a "neutral" rating and a $12.50 price target on the stock. Wall Street Zen raised Portage Biotech to a "hold" rating in a research report on Saturday, September 12th. Zacks Research upgraded Portage Biotech to a "hold" rating in a research note on Tuesday, August 18th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Portage Biotech in a research report on Friday, July 24th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Reduce" and a consensus price target of $12.50.
View Our Latest Stock Report on Portage Biotech
Portage Biotech Company Profile
(
Get Free Report)
Portage Biotech Inc is a clinical-stage biotechnology company focused on developing immuno-oncology treatments designed to stimulate the immune system to target and eliminate cancer cells. Its research has centered on therapies involving invariant natural killer T (iNKT) cells, a specialized immune-cell population that may help generate targeted antitumor responses.
The company's pipeline has included investigational therapies intended for use in solid tumors, including approaches that combine immune-cell activation with mechanisms designed to improve the tumor microenvironment and enhance treatment response.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
